-
2022 Prof. Hao Wang, ESMO |: After the advancement of the first-line treatment of HR+/HER2-ABC/MBC
Time of Update: 2022-10-03
In the TREnd study, researchers randomized HR+/HER2-advanced patients who had progressed prior to first- and second-line endocrine therapy (fluvixazole or AI monotherapy) and received a pipexil or pipexicil combined with a proendocrine regimen, and the results showed that the mPFS benefit of 6.
-
- predictors of primary drug resistance in metastatic breast cancer (MBC)
Time of Update: 2021-11-12
Recently, scholars from South Korea have carried out related studies to assess which clinical parameters can predict the primary drug resistance of palbociclib combined with letrozole as the first-line treatment of HR+ /HER2-MBC patients .
-
Front Oncol: The efficacy of trastuzumab biosimilar CT-P6 in HER2-positive early stage (EBC) and metastatic breast cancer (MBC) patients in the real world
Time of Update: 2021-11-02
Recently, Korean scholars have carried out related studies to evaluate the effectiveness of CT-P6 or trastuzumab (RTZ) combined with Pertuzumab chemotherapy in the neoadjuvant treatment of her2-positive EBC patients or the palliative first-line treatment of MBC patients Sex .
-
CSCO conference express a multicenter, retrospective study of pyrrotinib combined with vinorelbine in the treatment of HER2-positive MBC
Time of Update: 2021-10-10
There was no statistical difference in the median PFS of patients with second-line treatment and ≥third-line treatment, which is very close to the clinical study data of pyrrotinib and capecitabine .
-
Target CCR5 for breast cancer! Leonlimab has strong therapeutic potential in triple negative breast cancer (TNBC) and metastatic breast cancer (MBC)!
Time of Update: 2019-12-30
December 30, 2019 news / BIOON / -- cytodyn is a late clinical biotechnology company focusing on the development of a new humanized CCR5 antagonist, leonlimab (pro140), for a variety of treatment indi